{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:46Z","timestamp":1792290766722,"version":"4.4.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["00612631"],"award-info":[{"award-number":["00612631"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["26460675"],"award-info":[{"award-number":["26460675"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["15H03086"],"award-info":[{"award-number":["15H03086"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["23390149"],"award-info":[{"award-number":["23390149"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.neuropharm.2016.01.011","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T00:32:29Z","timestamp":1452040349000},"page":"264-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"special_numbering":"PB","title":["L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences"],"prefix":"10.1016","volume":"112","author":[{"given":"Hidetsugu","family":"Fujigaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.01.011_bib1","doi-asserted-by":"crossref","first-page":"e112945","DOI":"10.1371\/journal.pone.0112945","article-title":"Involvement of the kynurenine pathway in human glioma pathophysiology","volume":"9","author":"Adams","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbi.2015.07.016","article-title":"Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms","volume":"51","author":"Aeinehband","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.neuro.2007.07.010","article-title":"Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease","volume":"28","author":"Aguilera","year":"2007","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1432-1033.1996.0460u.x","article-title":"Isolation and expression of a cDNA clone encoding human kynureninase","volume":"239","author":"Alberati-Giani","year":"1996","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1046\/j.1471-4159.1996.66030996.x","article-title":"Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells","volume":"66","author":"Alberati-Giani","year":"1996","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4613-0381-7_28","article-title":"Regulation of the kynurenine pathway by IFN-gamma in murine cloned macrophages and microglial cells","volume":"398","author":"Alberati-Giani","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib7","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1523\/JNEUROSCI.5631-03.2004","article-title":"Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus","volume":"24","author":"Alkondon","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12974-014-0151-1","article-title":"The common inflammatory etiology of depression and cognitive impairment: a therapeutic target","volume":"11","author":"Allison","year":"2014","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuroscience.2008.11.055","article-title":"Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum","volume":"159","author":"Amori","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.biocel.2008.01.005","article-title":"Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway","volume":"41","author":"Ball","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1471-4159.1990.tb04553.x","article-title":"Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain","volume":"55","author":"Baran","year":"1990","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib13","doi-asserted-by":"crossref","first-page":"e0137022","DOI":"10.1371\/journal.pone.0137022","article-title":"Quinolinic acid responses during interferon-alpha-induced depressive symptomatology in patients with chronic hepatitis C infection \u2013 a novel aspect for depression and inflammatory hypothesis","volume":"10","author":"Baranyi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/bj2680437","article-title":"Glutamine synthesis from aspartate in guinea-pig renal cortex","volume":"268","author":"Baverel","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0304-4165(82)90379-8","article-title":"The preferred route of kynurenine metabolism in the rat","volume":"717","author":"Bender","year":"1982","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib17","doi-asserted-by":"crossref","first-page":"e82180","DOI":"10.1371\/journal.pone.0082180","article-title":"GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses","volume":"8","author":"Berlinguer-Palmini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-2999(88)90367-6","article-title":"Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor","volume":"154","author":"Birch","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12640-009-9051-z","article-title":"Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons","volume":"16","author":"Braidy","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnins.2014.00012","article-title":"Kynurenines in CNS disease: regulation by inflammatory cytokines","volume":"8","author":"Campbell","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0006-3223(03)00173-2","article-title":"Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment","volume":"54","author":"Capuron","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib23","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/QAD.0000000000000303","article-title":"Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment","volume":"28","author":"Cassol","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/schbul\/sbl033","article-title":"Elevations of endogenous kynurenic acid produce spatial working memory deficits","volume":"33","author":"Chess","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuro.2012.11.007","article-title":"3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system","volume":"34","author":"Colin-Gonzalez","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2010.10.009","article-title":"Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.","volume":"63","author":"Comai","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2008.06.007","article-title":"Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?","volume":"441","author":"Connor","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib29","doi-asserted-by":"crossref","first-page":"e14698","DOI":"10.1371\/journal.pone.0014698","article-title":"Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO)","volume":"6","author":"Croitoru-Lamoury","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib30","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1016\/S0021-9258(18)32486-4","article-title":"Transcriptional regulation of the tryptophan oxygenase gene in rat liver by glucocorticoids","volume":"258","author":"Danesch","year":"1983","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0197-0186(95)00091-7","article-title":"The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits","volume":"28","author":"de Carvalho","year":"1996","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3233\/JAD-2011-111097","article-title":"The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression","volume":"28","author":"Dobos","year":"2012","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0006-8993(89)90216-3","article-title":"Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line","volume":"495","author":"Eastman","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/BF01101711","article-title":"The role of hydrogen peroxide in the in\u00a0vitro cytotoxicity of 3-hydroxykynurenine","volume":"15","author":"Eastman","year":"1990","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0304-3940(01)02242-X","article-title":"Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia","volume":"313","author":"Erhardt","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001756-199701200-00011","article-title":"Activated human microglia produce the excitotoxin quinolinic acid","volume":"8","author":"Espey","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1964.tb05753.x","article-title":"Investigations on the tryptophane metabolism (via kynurenine) in schizophrenic patients","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3940(84)90050-8","article-title":"Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid","volume":"48","author":"Foster","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1471-4159.1986.tb02826.x","article-title":"Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in\u00a0vitro","volume":"47","author":"Foster","year":"1986","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jb\/mvj072","volume":"139","author":"Fujigaki","year":"2006","journal-title":"J.\u00a0Biochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib42","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1521-4141(200108)31:8<2313::AID-IMMU2313>3.0.CO;2-S","article-title":"Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism","volume":"31","author":"Fujigaki","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1128\/IAI.70.2.779-786.2002","article-title":"L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase","volume":"70","author":"Fujigaki","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib44","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib45","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1369\/0022155412458926","article-title":"Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis","volume":"60","author":"Fukunaga","year":"2012","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00964611","article-title":"L-kynurenine: its synthesis and possible regulatory function in brain","volume":"5","author":"Gal","year":"1980","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib47","doi-asserted-by":"crossref","first-page":"36554","DOI":"10.1074\/jbc.M113.503813","article-title":"Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain","volume":"288","author":"Giorgini","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib48","first-page":"635","article-title":"Photoinduced electron transfer reaction from N-formyl-L-kynurenine and L-kynurenine to cytochrome C.","volume":"15","author":"Goda","year":"1987","journal-title":"Biochem. Int."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib49","first-page":"441","article-title":"Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation","volume":"56","author":"Greilberger","year":"2010","journal-title":"Clin. Lab."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1471-4159.2007.04556.x","article-title":"Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain","volume":"102","author":"Guidetti","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib51","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4615-4709-9_18","article-title":"Kynurenine pathway metabolism in human astrocytes","volume":"467","author":"Guillemin","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1471-4159.2001.00498.x","article-title":"Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection","volume":"78","author":"Guillemin","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4615-0135-0_19","article-title":"Quinolinic acid in the pathogenesis of Alzheimer's disease","volume":"527","author":"Guillemin","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","article-title":"Kynurenine and its metabolites in Alzheimer's disease patients","volume":"55","author":"Gulaj","year":"2010","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib56","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1471-4159.1993.tb03269.x","article-title":"Identification of tryptophan 2,3-dioxygenase RNA in rodent brain","volume":"60","author":"Haber","year":"1993","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00018-009-0166-4","article-title":"Structure, expression, and function of kynurenine aminotransferases in human and rodent brains","volume":"67","author":"Han","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/978-1-4615-4709-9_49","article-title":"Indole-3-pyruvic and -propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers","volume":"467","author":"Hardeland","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuint.2006.08.012","article-title":"Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease","volume":"50","author":"Hartai","year":"2007","journal-title":"Neurochem. Int."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2016.01.011_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1042\/bj3200595","article-title":"Human microglia convert l-tryptophan into the neurotoxin quinolinic acid","volume":"320","author":"Heyes","year":"1996","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ana.410290215","article-title":"Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status","volume":"29","author":"Heyes","year":"1991","journal-title":"Ann. Neurol."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2016.01.011_bib62","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj3260351","article-title":"Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types","volume":"326","author":"Heyes","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1471-4159.1997.68010280.x","article-title":"Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues","volume":"68","author":"Heyes","year":"1997","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib64","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1046\/j.1471-4159.1997.69041519.x","article-title":"Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation","volume":"69","author":"Heyes","year":"1997","journal-title":"J.\u00a0Neurochem."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.01.011_bib65","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib66","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1096\/fasebj.12.10.881","article-title":"Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques","volume":"12","author":"Heyes","year":"1998","journal-title":"FASEB J."},{"issue":"Pt 3","key":"10.1016\/j.neuropharm.2016.01.011_bib67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj2830633","article-title":"Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid","volume":"283","author":"Heyes","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib68","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib69","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neures.2008.12.003","article-title":"Marked increases in hippocampal neuron indoleamine 2, 3-dioxygenase via IFN-gamma-independent pathway following transient global ischemia in mouse","volume":"63","author":"Hoshi","year":"2009","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib70","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/clinchem\/44.4.858","article-title":"Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients","volume":"44","author":"Huengsberg","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12640-015-9535-y","article-title":"Protective effect of spermidine against excitotoxic neuronal death induced by quinolinic acid in rats: possible neurotransmitters and neuroinflammatory mechanism","volume":"28","author":"Jamwal","year":"2015","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/IJTR.S16800","article-title":"Imbalanced kynurenine pathway in schizophrenia","volume":"7","author":"Kegel","year":"2014","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib73","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1471-4159.1989.tb01881.x","article-title":"A\u00a0glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists","volume":"52","author":"Kessler","year":"1989","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4419-8969-7_10","article-title":"Kynurenines in neurodegenerative disorders: therapeutic consideration","volume":"541","author":"Klivenyi","year":"2004","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2014.03.004","article-title":"A\u00a0systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats","volume":"82","author":"Koshy Cherian","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib76","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1523\/JNEUROSCI.1107-14.2014","article-title":"Reduction of brain kynurenic acid improves cognitive function","volume":"34","author":"Kozak","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib77","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-0028-1094391","article-title":"Kynurenines as probable participants of depression","volume":"6","author":"Lapin","year":"1973","journal-title":"Pharmakopsychiatr. Neuropsychopharmakol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib78","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/mp.2013.11","article-title":"The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression","volume":"19","author":"Lavebratt","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1742-2094-10-87","article-title":"Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors","volume":"10","author":"Lawson","year":"2013","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib80","doi-asserted-by":"crossref","first-page":"e14123","DOI":"10.1371\/journal.pone.0014123","article-title":"Characterisation of the expression of NMDA receptors in human astrocytes","volume":"5","author":"Lee","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuropharm.2015.10.028","article-title":"Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons","volume":"102","author":"Linderholm","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib82","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/schbul\/sbq086","article-title":"Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia","volume":"38","author":"Linderholm","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib83","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.bbadis.2015.02.001","article-title":"Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity","volume":"1852","author":"Liu","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00262-008-0513-6","article-title":"IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism","volume":"58","author":"Lob","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib85","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","article-title":"On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress","volume":"33","author":"Lugo-Huitron","year":"2011","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib86","doi-asserted-by":"crossref","first-page":"104024","DOI":"10.1155\/2013\/104024","article-title":"Quinolinic acid: an endogenous neurotoxin with multiple targets","volume":"2013","author":"Lugo-Huitron","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5114\/ceji.2014.42115","article-title":"Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice","volume":"39","author":"Malaczewska","year":"2014","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib88","doi-asserted-by":"crossref","first-page":"e0130715","DOI":"10.1371\/journal.pone.0130715","article-title":"Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis","volume":"10","author":"Mancuso","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib89","article-title":"Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder","author":"Meier","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib90","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","article-title":"Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib91","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1258\/0004563011900461","article-title":"3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma","volume":"38","author":"Morita","year":"2001","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00702-011-0763-x","article-title":"Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery","volume":"119","author":"Moroni","year":"2012","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4137\/IJTR.S11558","article-title":"Species and cell types difference in tryptophan metabolism","volume":"6","author":"Murakami","year":"2013","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib94","doi-asserted-by":"crossref","first-page":"32ps23","DOI":"10.1126\/scitranslmed.3001082","article-title":"Insights into therapy: tryptophan oxidation and HIV infection","volume":"2","author":"Murray","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib95","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jad.2006.07.013","article-title":"Kynurenine pathway in major depression: evidence of impaired neuroprotection","volume":"98","author":"Myint","year":"2007","journal-title":"J.\u00a0Affect Disord."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib96","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-211-45295-0_45","article-title":"Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies","author":"Nemeth","year":"2006","journal-title":"J.\u00a0Neural Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2005.07.013","article-title":"Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia","volume":"80","author":"Nilsson","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib98","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1523\/JNEUROSCI.5032-08.2009","article-title":"Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin","volume":"29","author":"O'Connor","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib99","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.mp.4002148","article-title":"Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice","volume":"14","author":"O'Connor","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib100","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.93.22.12553","article-title":"Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine","volume":"93","author":"Okuda","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib101","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-8993(91)91583-M","article-title":"Two kynurenine aminotransferases in human brain","volume":"542","author":"Okuno","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib102","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1835799","article-title":"NMDA antagonist neurotoxicity: mechanism and prevention","volume":"254","author":"Olney","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib104","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/IAI.62.4.1131-1136.1994","article-title":"Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures","volume":"62","author":"Paguirigan","year":"1994","journal-title":"Infect. Immun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fpsyt.2015.00116","article-title":"Kynurenine 3-monooxygenase: an influential mediator of neuropathology","volume":"6","author":"Parrott","year":"2015","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib106","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: a clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-079X.2008.00580.x","article-title":"Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species","volume":"45","author":"Peyrot","year":"2008","journal-title":"J.\u00a0Pineal Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/jir.1986.6.267","article-title":"Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts","volume":"6","author":"Pfefferkorn","year":"1986","journal-title":"J.\u00a0Interferon Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib109","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbapap.2010.12.003","article-title":"Structure, mechanism, and substrate specificity of kynureninase","volume":"1814","author":"Phillips","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.expneurol.2010.03.009","article-title":"Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats","volume":"224","author":"Pierozan","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1471-4159.2001.00057.x","article-title":"N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition","volume":"76","author":"Pittaluga","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib112","doi-asserted-by":"crossref","first-page":"e6344","DOI":"10.1371\/journal.pone.0006344","article-title":"The excitotoxin quinolinic acid induces tau phosphorylation in human neurons","volume":"4","author":"Rahman","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib113","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/mp.2009.116","article-title":"CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression","volume":"15","author":"Raison","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib114","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1471-4159.2005.03134.x","article-title":"Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum","volume":"93","author":"Rassoulpour","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuro.2015.08.003","article-title":"Mitochondrial dysfunction related to cell damage induced by 3-hydroxykynurenine and 3-hydroxyanthranilic acid: non-dependent-effect of early reactive oxygen species production","volume":"50","author":"Reyes-Ocampo","year":"2015","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib116","doi-asserted-by":"crossref","first-page":"646909","DOI":"10.1155\/2014\/646909","article-title":"Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases","volume":"2014","author":"Reyes Ocampo","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0922-4106(89)90040-0","article-title":"NMDA receptor antagonists that bind to the strychnine-insensitive glycine site and inhibit NMDA-induced Ca2+ fluxes and [3H]GABA release","volume":"172","author":"Reynolds","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib118","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/BF00966592","article-title":"Quinolinic acid is a potent lipid peroxidant in rat brain homogenates","volume":"16","author":"Rios","year":"1991","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib119","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-1-4613-0381-7_75","article-title":"Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis","volume":"398","author":"Saito","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0006-8993(91)90536-5","article-title":"Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques","volume":"540","author":"Saito","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib121","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(91)91171-V","article-title":"Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice","volume":"546","author":"Saito","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib122","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0306-4522(92)90467-G","article-title":"Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse","volume":"51","author":"Saito","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1471-4159.1993.tb05836.x","article-title":"Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia","volume":"60","author":"Saito","year":"1993","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib124","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/j.1471-4159.1993.tb07443.x","article-title":"Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation","volume":"61","author":"Saito","year":"1993","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/abbi.1993.1567","article-title":"Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia","volume":"307","author":"Saito","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1042\/bj2290499","article-title":"The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes","volume":"229","author":"Salter","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib127","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/00001756-200103260-00049","article-title":"Quinolinic acid induces oxidative stress in rat brain synaptosomes","volume":"12","author":"Santamaria","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib128","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1097\/00001756-200108280-00020","article-title":"In\u00a0vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum","volume":"12","author":"Santamaria","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","article-title":"Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia","volume":"37","author":"Sathyasaikumar","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib131","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.07.609","article-title":"Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder","volume":"62","author":"Savitz","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib132","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.psyneuen.2014.11.015","article-title":"Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder","volume":"52","author":"Savitz","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib133","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/npp.2014.194","article-title":"Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder","volume":"40","author":"Savitz","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbi.2015.02.007","article-title":"Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder","volume":"46","author":"Savitz","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/138920007780362608","article-title":"Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection","volume":"8","author":"Schroecksnadel","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib136","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib137","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(83)90115-5","article-title":"Differential vulnerability of central neurons of the rat to quinolinic acid","volume":"38","author":"Schwarcz","year":"1983","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib138","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","article-title":"Increased cortical kynurenate content in schizophrenia","volume":"50","author":"Schwarcz","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib139","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1503\/jpn.140126","article-title":"Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia\u2013significance for activation of the kynurenine pathway","volume":"40","author":"Schwieler","year":"2015","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib141","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.npp.1300188","article-title":"Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat","volume":"28","author":"Shepard","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib142","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/S0021-9258(17)30447-7","article-title":"Indoleamine 2,3-dioxygenase. Purification and some properties","volume":"253","author":"Shimizu","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib143","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.intimp.2011.02.005","article-title":"L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species","volume":"11","author":"Song","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib144","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1523\/JNEUROSCI.09-06-02066.1989","article-title":"High-affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes","volume":"9","author":"Speciale","year":"1989","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib145","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1471-4159.1990.tb13296.x","article-title":"Uptake of kynurenine into rat brain slices","volume":"54","author":"Speciale","year":"1990","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib146","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1111\/j.1460-9568.2007.05540.x","article-title":"Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats","volume":"25","author":"Stone","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib147","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib148","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","article-title":"Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS","volume":"72","author":"Stone","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib149","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2005.09.032","article-title":"Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism","volume":"338","author":"Takikawa","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib151","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)77982-4","article-title":"Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity","volume":"263","author":"Takikawa","year":"1988","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib152","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0197-0186(01)00133-4","article-title":"Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes","volume":"40","author":"Tavares","year":"2002","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib153","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00001756-200002070-00005","article-title":"Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain","volume":"11","author":"Tavares","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib154","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1096\/fasebj.5.11.1907934","article-title":"Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism","volume":"5","author":"Taylor","year":"1991","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1742-2094-6-36","article-title":"Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease","volume":"6","author":"Ting","year":"2009","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib156","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0014-5793(97)00374-8","article-title":"Cloning and recombinant expression of rat and human kynureninase","volume":"408","author":"Toma","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib157","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1203\/PDR.0b013e3181be9e7e","article-title":"Tryptophan released from mother's milk has antioxidant properties","volume":"66","author":"Tsopmo","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib158","doi-asserted-by":"crossref","first-page":"22021","DOI":"10.1074\/jbc.M603503200","article-title":"Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35","volume":"281","author":"Wang","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib159","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.mp.4001600","article-title":"IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity","volume":"10","author":"Wichers","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib160","first-page":"11","article-title":"The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression","volume":"29","author":"Wichers","year":"2004","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib161","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s007020200014","article-title":"Increased neopterin production and tryptophan degradation in advanced Parkinson's disease","volume":"109","author":"Widner","year":"2002","journal-title":"J.\u00a0Neural Transm. Vienna"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4615-4709-9_19","article-title":"Degradation of tryptophan in neurodegenerative disorders","volume":"467","author":"Widner","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib163","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2013.03.007","article-title":"Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations","volume":"329","author":"Wissmann","year":"2013","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib164","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jamcollsurg.2008.12.018","article-title":"Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target","volume":"208","author":"Witkiewicz","year":"2009","journal-title":"J.\u00a0Am. Coll. Surg."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archgenpsychiatry.2011.71","article-title":"Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes","volume":"68","author":"Wonodi","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib166","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/bj2300635","article-title":"Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme","volume":"230","author":"Yamazaki","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib167","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/MCB.24.16.6919-6930.2004","article-title":"Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice","volume":"24","author":"Yu","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib168","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gene.2005.09.034","article-title":"Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family","volume":"365","author":"Yu","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib169","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00239-007-9049-1","article-title":"Evolution of vertebrate indoleamine 2,3-dioxygenases","volume":"65","author":"Yuasa","year":"2007","journal-title":"J.\u00a0Mol. Evol."},{"key":"10.1016\/j.neuropharm.2016.01.011_bib170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/npp.2011.277","article-title":"Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis","volume":"37","author":"Zunszain","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.01.011_bib171","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816300119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816300119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T20:14:21Z","timestamp":1654028061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816300119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":171,"alternative-id":["S0028390816300119"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.01.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}